Last reviewed · How we verify

LIDOCAINE 1 %

Ain Shams Maternity Hospital · FDA-approved active Small molecule

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Local anesthesia for infiltration, nerve blocks, and topical application, Pain relief during minor surgical and dental procedures.

At a glance

Generic nameLIDOCAINE 1 %
Also known asXYLOCAINE
SponsorAin Shams Maternity Hospital
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby preventing depolarization and blocking the generation and propagation of action potentials. This reversible blockade of nerve conduction results in loss of sensation in the area where it is applied or injected. The effect is localized and temporary, wearing off as the drug is metabolized and redistributed.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: